Sign inJoin waitlistJoin the waitlist

ZM

Zahi Mitri

Hematology & Oncology

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
2014–2017
Internal Medicine
Emory University
2011–2014
Doctor of Medicine
2006–2010

Research

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
Chemotherapy Research and Practice · 2012 · First of 3 authors · 335 citations
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications · 2023 · 62 citations
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer
Investigational New Drugs · 2015 · First of 10 authors · 61 citations

Gordon Mills
9 papers
AG
Alexander Guimaraes
5 papers
CC
Christopher Corless
5 papers
Raymond Bergan
5 papers
Allen Li
4 papers · 4 as a fellow
TB
Tomasz Beer
3 papers
BK
Ben Kong
2 papers
Brie Chun
2 papers · 2 as a fellow
CL
Charles Lopez
2 papers
Claire Smith
2 papers · 2 as a fellow
DR
Dr Ribkoff
2 papers · 1 as a resident
Evie Hobbs
2 papers · 1 as a fellow

Clinical trials

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
Principal investigator · Completed · Phase 1
OHSU Knight Cancer Institute
2018–2020